These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

217 related articles for article (PubMed ID: 30941515)

  • 1. The Emerging Role of Minimal Residual Disease Testing in Diffuse Large B-Cell Lymphoma.
    Hu R; Winter A; Hill BT
    Curr Oncol Rep; 2019 Apr; 21(5):44. PubMed ID: 30941515
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Circulating Tumor DNA in Diffuse Large B-Cell Lymphoma: from Bench to Bedside?
    Cherng HJ; Herrera A
    Curr Treat Options Oncol; 2024 May; 25(5):659-678. PubMed ID: 38656685
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Circulating tumor DNA: clinical roles in diffuse large B cell lymphoma.
    Wu FT; Lu L; Xu W; Li JY
    Ann Hematol; 2019 Feb; 98(2):255-269. PubMed ID: 30368587
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Circulating Tumor DNA to Monitor Therapy for Aggressive B-Cell Lymphomas.
    Kwok M; Wu SP; Mo C; Summers T; Roschewski M
    Curr Treat Options Oncol; 2016 Sep; 17(9):47. PubMed ID: 27461036
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The value of liquid biopsy in diagnosis and monitoring of diffuse large b-cell lymphoma: recent developments and future potential.
    Camus V; Jardin F; Tilly H
    Expert Rev Mol Diagn; 2017 Jun; 17(6):557-566. PubMed ID: 28415895
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Diffuse large B-cell lymphoma: Time to focus on circulating blood nucleic acids?
    Regazzo G; Marchesi F; Spagnuolo M; Díaz Méndez AB; Masi S; Mengarelli A; Rizzo MG
    Blood Rev; 2021 May; 47():100776. PubMed ID: 33229139
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Tracking the evolution of untreated high-intermediate/high-risk diffuse large B-cell lymphoma by circulating tumour DNA.
    Zhang S; Zhang T; Liu H; Zhao J; Zhou H; Su X; Liu X; Li L; Qiu L; Qian Z; Zhou S; Gong W; Meng B; Ren X; He J; Wang X; Zhang H
    Br J Haematol; 2022 Feb; 196(3):617-628. PubMed ID: 34664256
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Noninvasive minimal residual disease assessment in relapsed/refractory large B-cell lymphoma using digital droplet PCR.
    Heger JM; d'Hargues Y; Kleinert F; Mattlener J; Weiss J; Franzen F; Becker C; Becker K; Gödel P; Schmiel M; Meinel J; Flümann R; Simon F; Reinhardt HC; Borchmann P; Borchmann S; Balke-Want H; Knittel G; von Tresckow B
    Eur J Haematol; 2024 Jun; 112(6):957-963. PubMed ID: 38369814
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Minimal residual disease detection by flow cytometry and PARR in lymph node, peripheral blood and bone marrow, following treatment of dogs with diffuse large B-cell lymphoma.
    Aresu L; Aricò A; Ferraresso S; Martini V; Comazzi S; Riondato F; Giantin M; Dacasto M; Guadagnin E; Frayssinet P; Rouquet N; Drigo M; Marconato L
    Vet J; 2014 May; 200(2):318-24. PubMed ID: 24698669
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical implications of circulating tumor DNA in predicting the outcome of diffuse large B cell lymphoma patients receiving first-line therapy.
    Li M; Mi L; Wang C; Wang X; Zhu J; Qi F; Yu H; Ye Y; Wang D; Cao J; Hu D; Yang Q; Zhao D; Ma T; Song Y; Zhu J
    BMC Med; 2022 Oct; 20(1):369. PubMed ID: 36280874
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Monitoring clinical outcomes in aggressive B-cell lymphoma: From imaging studies to circulating tumor DNA.
    Melani C; Wilson WH; Roschewski M
    Best Pract Res Clin Haematol; 2018 Sep; 31(3):285-292. PubMed ID: 30213398
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Noninvasive monitoring of diffuse large B-cell lymphoma by immunoglobulin high-throughput sequencing.
    Kurtz DM; Green MR; Bratman SV; Scherer F; Liu CL; Kunder CA; Takahashi K; Glover C; Keane C; Kihira S; Visser B; Callahan J; Kong KA; Faham M; Corbelli KS; Miklos D; Advani RH; Levy R; Hicks RJ; Hertzberg M; Ohgami RS; Gandhi MK; Diehn M; Alizadeh AA
    Blood; 2015 Jun; 125(24):3679-87. PubMed ID: 25887775
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Aberrant DNA methylation of the p57KIP2 gene is a sensitive biomarker for detecting minimal residual disease in diffuse large B cell lymphoma.
    Hagiwara K; Li Y; Kinoshita T; Kunishma S; Ohashi H; Hotta T; Nagai H
    Leuk Res; 2010 Jan; 34(1):50-4. PubMed ID: 19616848
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Liquid biopsy in tissue-born lymphomas.
    Spina V; Rossi D
    Swiss Med Wkly; 2019 Jan; 149():w14709. PubMed ID: 30673117
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Diffuse large B-cell lymphoma.
    Li S; Young KH; Medeiros LJ
    Pathology; 2018 Jan; 50(1):74-87. PubMed ID: 29167021
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Distinct biological subtypes and patterns of genome evolution in lymphoma revealed by circulating tumor DNA.
    Scherer F; Kurtz DM; Newman AM; Stehr H; Craig AF; Esfahani MS; Lovejoy AF; Chabon JJ; Klass DM; Liu CL; Zhou L; Glover C; Visser BC; Poultsides GA; Advani RH; Maeda LS; Gupta NK; Levy R; Ohgami RS; Kunder CA; Diehn M; Alizadeh AA
    Sci Transl Med; 2016 Nov; 8(364):364ra155. PubMed ID: 27831904
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cell-free DNA as a biomarker in diffuse large B-cell lymphoma: A systematic review.
    Arzuaga-Mendez J; Prieto-Fernández E; Lopez-Lopez E; Martin-Guerrero I; García-Ruiz JC; García-Orad A
    Crit Rev Oncol Hematol; 2019 Jul; 139():7-15. PubMed ID: 31112884
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Measurable Residual Disease Monitoring in Lymphoma.
    Cuzzo B; Lipsky A; Cherng HJ
    Curr Hematol Malig Rep; 2023 Dec; 18(6):292-304. PubMed ID: 37930608
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Minimal residual disease in non-Hodgkin lymphoma - current applications and future directions.
    Chase ML; Armand P
    Br J Haematol; 2018 Jan; 180(2):177-188. PubMed ID: 29076131
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The Role of Minimal Residual Disease Testing in Myeloma Treatment Selection and Drug Development: Current Value and Future Applications.
    Anderson KC; Auclair D; Kelloff GJ; Sigman CC; Avet-Loiseau H; Farrell AT; Gormley NJ; Kumar SK; Landgren O; Munshi NC; Cavo M; Davies FE; Di Bacco A; Dickey JS; Gutman SI; Higley HR; Hussein MA; Jessup JM; Kirsch IR; Little RF; Loberg RD; Lohr JG; Mukundan L; Omel JL; Pugh TJ; Reaman GH; Robbins MD; Sasser AK; Valente N; Zamagni E
    Clin Cancer Res; 2017 Aug; 23(15):3980-3993. PubMed ID: 28428191
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.